CLINICAL CASE STUDY
First-Line Treatment Selection
for a Patient With Metastatic
Pancreatic Cancer
A SUPPLEMENT TO VOL. 32 SUPPL. 9
This supplement is sponsored by Celgene Corporation.
This promotional program was developed by Celgene
Corporation with input from John Marshall, MD.
John Marshall, MD, is a global leader in the research
and development of drugs for colon cancer and other
GI cancers. He is the principal investigator of over
150 clinical trials and is widely published in the field
of clinical oncology. He reviews manuscripts for eight
journals and holds peer-reviewed grants from the
National Institutes of Health.
Dr. Marshall received his training at Duke University,
the University of Louisville, and Georgetown University.
Dr. Marshall is an internationally recognized expert in
new drug development for GI cancer, with expertise
in phase I, II, and III trial design, and has served as
Principal Investigator for more than one hundred
clinical trials. Dr. Marshall has become an outspoken
advocate for GI cancer patients and the importance of
clinical research participation. Most recently, he has
established the Otto J Ruesch Center for the Cure of GI
Cancers, an organization solely focused on improving
the lives of GI cancer patients.
Dr. Marshall received a fee for his participation in
this program.
Featured Expert
JOHN MARSHALL, MD
Medical Oncologist
Washington, DC
“Pancreatic cancer continues to be a medical challenge with limited treatment
options, and the difficulty of treating it is compounded by the fact that so
many patients are diagnosed at a late stage. ABRAXANE plus gemcitabine
offers an important first-line option for metastatic pancreatic patients who you
may often see in clinical practice. In this supplement, we discuss the case
of a patient who may benefit from ABRAXANE plus gemcitabine as first-line
treatment for metastatic pancreatic adenocarcinoma.”
• Do not administer ABRAXANE therapy to patients who have baseline neutrophil counts of less than 1500
cells/mm3. In order to monitor the occurrence of bone marrow suppression, primarily neutropenia, which
may be severe and result in infection, it is recommended that frequent peripheral blood cell counts be
performed on all patients receiving ABRAXANE
• Note: An albumin form of paclitaxel may substantially affect a drug’s functional properties relative to those
of drug in solution. DO NOT SUBSTITUTE FOR OR WITH OTHER PACLITAXEL FORMULATIONS
INDICATION
ABRAXANE is indicated for the first-line treatment of patients with
metastatic adenocarcinoma of the pancreas, in combination with gemcitabine.
